NCT06921850View on ClinicalTrials.gov

A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa

PHASE3RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

April 7, 2025

Primary Completion Date

March 19, 2027

Study Completion Date

May 30, 2029

Conditions
Hidradenitis Suppurativa
Interventions
DRUG

Bimekizumab

Bimekizumab will be administered at pre-specified timepoints.

Trial Locations (13)

10023

RECRUITING

Hs0006 50712, Brooklyn

27516

RECRUITING

Hs0006 50706, Chapel Hill

45324

RECRUITING

Hs0006 50202, Fairborn

48059

RECRUITING

Hs0006 50710, Fort Gratiot

48084

RECRUITING

Hs0006 50711, Troy

48346

RECRUITING

Hs0006 50178, Clarkston

76011

RECRUITING

Hs0006 50201, Arlington

85006

RECRUITING

Hs0006 50175, Phoenix

95661

RECRUITING

Hs0006 50708, Roseville

Unknown

RECRUITING

Hs0006 40625, Lodz

RECRUITING

Hs0006 40761, Warsaw

RECRUITING

Hs0006 40095, Wroclaw

RECRUITING

Hs0006 40845, Wroclaw

All Listed Sponsors
lead

UCB Biopharma SRL

INDUSTRY